CardiomyopathyAtrial systole and left ventricular filling in hypertrophic cardiomyopathy: Effect of verapamil
References (22)
- et al.
Left ventricular relaxation and filling in different forms of left ventricular hypertrophy: an echocardiographic study
Am J Cardiol
(1980) - et al.
Arrhythmia in hypertrophic cardiomyopathy; exercise and 48-hour ambulatory electrocardicgraphic assessment with and without beta adrenergic blocking therapy
Am J Cardiol
(1980) - et al.
Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy
Am J Cardiol
(1980) - et al.
Hypertrophic cardiomyopathy: recent observations regarding the specificity of three hallmarks of the disease: asymmetric septal hypertrophy, septal disorganization, and systolic anterior motion of the anterior mitral leaflet
Am J Cardiol
(1980) - et al.
Instrumentation and data processing in cardiovascular nuclear medicine; evaluation of ventricular function
- et al.
Automated analysis of the left ventricular diameter time curve from echocardiographic recordings
Comput Biomed Res
(1976) - et al.
Impaired rate of left ventricular filling in idiopathic hypertrophic subaortic stenosis and valvular aortic stenosis
Circulation
(1968) - et al.
Correlations of etectrocardtographic pattern, shape of ventricular septum, and isovolumic relaxation time in irregular hypertropic cardiomyopathy (obstructive cardiomyopathy)
Br Heart J
(1971) - et al.
Left ventricular filling in hypertropic cardiomyopathy: an angiographic study
Br Heart J
(1977) - et al.
Left ventricular relaxation and filling in hypertrophic cardiomyopathy: an echocardiographic study
Br Heart J
(1978)
Echocardiographic assessment of left ventricular filling and septal and posterior wall dynamics in idiopathic hypertrophic subaortic stenosis
Circulation
Cited by (174)
Extent and magnitude of low-voltage areas assessed by ultra-high-density electroanatomical mapping correlate with left atrial function
2018, International Journal of CardiologyCitation Excerpt :In a recent consensus statement of the EHRA, AR has been defined as ‘any complex of structural, architectural, contractile or electrophysiological changes affecting the atria with the potential to produce clinically-relevant manifestations’ [1]. AR is independently associated with increased mortality and patient deterioration [2,3] and has been linked to disease progression and arrhythmias (e.g. AF) [4–7]. Current evidence indicates that atrial function extends beyond the classical view of an “atrial kick” to improve ventricular filling [1].
Predictors of future onset of atrial fibrillation in hypertrophic cardiomyopathy
2018, Archives of Cardiovascular DiseasesCitation Excerpt :A series of prospective studies have identified predictors of future AF development in patients with HCM, including age [9], heart failure symptoms [5,10], N-terminal pro B-type natriuretic peptide concentration or P wave dispersion on electrocardiography [11], as well as left atrial (LA) size and phasic function on imaging [9,11]. The mechanism leading to AF in HCM patients is thought to be mediated by atrial remodelling secondary to left ventricular (LV) diastolic dysfunction [12]. However, although comparative studies have reported higher prevalence [13] and burden [14] of LV fibrosis on CMR in HCM patients with AF, a relationship between the ventricular HCM phenotype and AF occurrence has not been confirmed prospectively.
Advances in medical treatment of hypertrophic cardiomyopathy
2014, Journal of CardiologyCitation Excerpt :Kaltenbach et al. reported that the long-term use of verapamil improved the clinical symptoms and LV function in patients with HOCM [50]. It is acknowledged that verapamil improves LV diastolic function in the early diastolic phase [51–53]. The intracellular Ca2+ concentration of myocytes is known to be very high in patients with HCM, and appears to be related to abnormal LV diastolic dysfunction [54,55].
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America
2011, Journal of the American College of Cardiology2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology
2011, Journal of the American College of CardiologyCitation Excerpt :Possible mechanisms for symptomatic improvement include negative inotropic and rate-lowering effects similar to those of beta blockers. However, the effect of verapamil on diastolic dysfunction is controversial (258–262). Diltiazem has also been shown to improve measures of diastolic performance (263) and to prevent or diminish myocardial ischemia (264).
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy
2011, Journal of Thoracic and Cardiovascular Surgery